Ticker Symbol: TOS/TSX
Shares Outstanding: 58,027,389
QUEBEC CITY, May 19 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in sterilization technology for medical
devices in healthcare settings is pleased to announce that the company
and 3M™ Infection Prevention Division have amended their December 2009
Global Agreement to include a second product, which is currently in
development and destined for use in the operating room (OR). In
addition, the companies have agreed to explore the industrial and
scientific markets to determine commercial opportunities for the
current product (3M™ Optreoz 125-Z).
"We are pleased that 3M™ has selected to expand their portfolio of
products based on the TSO3 technology," commented R.M. (Ric) Rumble, TSO3's President and CEO. "The sterilizer in development is designed to be a
true solution to the reprocessing needs of the OR and with this
agreement, it will be supported by a globally experienced and
professional sales team," Mr. Rumble added. "The amendment to the
contract also allows 3M™ and TSO3 to explore opportunities in the industrial and scientific market
TSO3 has previously disclosed only limited details on the small,
"purpose-built", sterilizer currently in development and targeted at
the OR market. This product will enable terminal sterilization of
packaged complex medical devices such as powered instruments, imaging
accessories, as well as complex and expensive rigid and flexible
endoscopes currently sterilized in OR sub-sterile reprocessing areas of
acute care facilities.
While visiting the TSO3 headquarters in Québec City and touring the plant, Debra A.
Rectenwald, President and General Manager of the 3M™ Infection
Prevention Division commented: "We are pleased to further our work
with TSO3 in the OR through the amendment to our original agreement. 3M™ and TSO3 have collaborated closely in preparing to launch the 3M™ Optreoz™ 125-Z
in markets where regulatory clearances have been obtained. Together,
we plan to leverage our mutual expertise and knowledge in the critical
OR space through this agreement."
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument
sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital
environment and offers an advantageous replacement solution to other
low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts (including, without
limitation, those regarding the timing or outcome of any financing
undertaken by TSO3) are forward-looking statements that involve certain risks,
uncertainties and hypotheses, including, but not limited to, general
business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other risks and
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
SOURCE TSO3 INC.
For further information:
Source: TSO3 Inc.
Director, Corporate Communications
418 651-0003, Ext. 237